- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | SIRNAOMICS-B (02257): TERMS OF REFERENCE FOR NOMINATION COMMITTEE UNDER THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 25.04. | SIRNAOMICS-B (02257): PROXY FORM | 1 | HKEx | ||
| 25.04. | SIRNAOMICS-B (02257): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2024 | - | HKEx | ||
| 25.04. | SIRNAOMICS-B (02257): ANNUAL REPORT 2024 | - | HKEx | ||
| SIRNAOMICS Aktie jetzt für 0€ handeln | |||||
| 25.04. | SIRNAOMICS-B (02257): PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND BUY BACK SHARES, PROPOSED RE-ELECTION OF DIRECTORS, PROPOSED RE-APPOINTMENT ... | - | HKEx | ||
| 25.04. | SIRNAOMICS-B (02257): NOTICE OF ANNUAL GENERAL MEETING | 2 | HKEx | ||
| 23.04. | SIRNAOMICS-B (02257): CESSATION OF HONORARY SCIENTIFIC ADVISOR | - | HKEx | ||
| 27.03. | SIRNAOMICS-B (02257): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 | - | HKEx | ||
| 18.03. | SIRNAOMICS-B (02257): REMEDIAL ACTIONS ON INTERNAL CONTROL WEAKNESSES AND DEFICIENCIES | - | HKEx | ||
| 17.03. | SIRNAOMICS-B (02257): NOTICE OF BOARD MEETING | - | HKEx | ||
| 19.02. | SIRNAOMICS-B (02257): CHANGE IN COMPOSITION OF BOARD COMMITTEE AND COMPLIANCE WITH LISTING RULES | 1 | HKEx | ||
| 17.02. | SIRNAOMICS-B (02257): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 17.02. | SIRNAOMICS-B (02257): APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR, CHANGES IN COMPOSITION OF BOARD COMMITTEES AND UPDATE ON COMPLIANCE WITH LISTING ... | 1 | HKEx | ||
| 05.02. | SIRNAOMICS-B (02257): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 05.02. | SIRNAOMICS-B (02257): RESIGNATION OF NON-EXECUTIVE DIRECTOR, CHANGES IN COMPOSITION OF BOARD COMMITTEE AND CHANGE OF AUTHORIZED REPRESENTATIVE | 2 | HKEx | ||
| 13.01. | SIRNAOMICS-B (02257): INTERIM KEY FINDINGS OF INDEPENDENT INVESTIGATION | 1 | HKEx | ||
| 01.01. | SIRNAOMICS-B (02257): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 01.01. | SIRNAOMICS-B (02257): NON-COMPLIANCE WITH THE LISTING RULES | 3 | HKEx | ||
| 30.12.24 | SIRNAOMICS-B (02257): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 30, 2024 | 2 | HKEx | ||
| 13.12.24 | SIRNAOMICS-B (02257): CHANGE OF AUDITOR | 1 | HKEx |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
| ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
| TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales | ||
| BIONTECH | 95,35 | +0,05 % | Summit Therapeutics crasht - BioNTech in Sippenhaft | Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die... ► Artikel lesen | |
| VERA THERAPEUTICS | 22,760 | -25,69 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 46,880 | -3,99 % | ROUNDUP/Aktien New York: Knappes Plus - Gelassenheit trotz Zoll-Unruhen | NEW YORK (dpa-AFX) - Die US-Börsen haben am Dienstag knappe Kursgewinne erzielt. Die jüngst wieder aufflackernden, internationalen Handelsstreitigkeiten wegen der amerikanischen Zollpolitik scheinen... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 15,240 | +2,83 % | RBC Capital behält Outperform-Rating für Edgewise Therapeutics-Aktie bei | ||
| JANUX THERAPEUTICS | 26,210 | +5,86 % | Leerink cuts Janux Therapeutics price target to $89, keeps Outperform | ||
| EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
| 89BIO | 10,250 | +3,12 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| TREVI THERAPEUTICS | 7,060 | +4,75 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p
Patients saw a... ► Artikel lesen |
Das Unternehmen SIRNAOMICS LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,396 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SIRNAOMICS LTD finden Sie auf Wallstreet Online.